Senti Biosciences, Inc. (SNTI)
(Real Time Quote from BATS)
$1.71 USD
-0.03 (-1.72%)
Updated Aug 5, 2025 02:22 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNTI 1.71 -0.03(-1.72%)
Will SNTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNTI
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
SNTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SNTI
SNTI Advances SENTI-202 to Phase 2 Dosage in Ongoing Clinical Study
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the ...
Senti Bio confirms recommended RP2D in Phase 1 study of SENTI-202
Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. ...